Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

Market Cap	21.92B +3.2%
Revenue (ttm)	8.24B -3.1%
Net Income	1.11B +15.7%
EPS	0.74 +15.7%
Shares Out	1.49B
PE Ratio	19.82
Forward PE	12.54
Dividend	0.53 (3.61%)
Ex-Dividend Date	Oct 17, 2025

Volume	6,881,120
Average Volume	9,416,876
Open	14.84
Previous Close	14.78
Day's Range	14.66 - 14.86
52-Week Range	14.13 - 17.69
Beta	0.46
RSI	33.94
Earnings Date	Mar 20, 2026

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells medicines and related pharmaceuticals in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 10,958
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600535

Financial Performance

In 2025, SHA:600535's revenue was 8.24 billion, a decrease of -3.08% compared to the previous year's 8.50 billion. Earnings were 1.11 billion, an increase of 15.68%.